1 / 16

A Framework for Device-Based Clinical Research in Image-Guided Therapies

This paper proposes a framework for device-based, minimally invasive cancer therapies using real-time intra-procedural imaging. It explores the potential clinical utilities in interventional oncology and highlights the need for clinical trials support in this field.

sidneym
Download Presentation

A Framework for Device-Based Clinical Research in Image-Guided Therapies

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. A Framework for Device-Based Clinical Research in Image-Guided Therapies Keyvan Farahani, PhD Gary Dorfman, MD Image-Guided Interventions Branch Cancer Imaging Program NCI

  2. Interventional Oncology (IO) • IGI Defined:Device-based, minimally-, non-invasive cancer therapies* that use real-, or near real-time intra-procedural imaging for localization, targeting, monitoring, control, and endpoint determination. * not just IR – also RT, endoscopy, surgery, etc.

  3. Interventional Oncology • Potential Clinical Utilities: • Primary Palliation (Bone Mets, Celiac Axis Block) • Secondary Palliation (PCN, PBD, G-, J-tubes) • Adjunctive Therapy (PV Embolization, Access) • Bridge to Definitive Rx (HCC) • Cure (Early / Screen Detected CA, Pre-CA, Indeterminate Lesions) • Intermediate Facilitator for Development of Molecularly Targeted Therapies

  4. Molecular Imaging (and Intervention?) Imaging Probe Cell Targeted Therapy Molecular Signature of Cancer Imaging Device (IGI Device?)

  5. NCI Support for IO: Current Environment • CTWG / TRWG / Multi-PI Initiative • Existing PAs • R01 / SBIR / STTR • Platform Development, Clinical Trials • Now Two Quick Trials Mechanisms • However, Current Payline is Dismal… • NCI Unique in Offering Clinical Trials Support Outside of Investigator Initiated Mechanisms • “I2” Imaging Initiatives, Including: • IO Clinical Trials Support • Informatics (caBIG, NCIA, databases, analysis algorithms)

  6. NCI IO Initiatives: Current • CIP IGI Branch Initiatives • Largely Basic Science Through Investigator Initiated Pathways • Discovery, Development, Delivery • Translational Research (inc. Early Trials) • Clinical Trials Infrastructure • Targeted Towards Image-Guided, Device-Based Therapy Similar to the Infrastructure Provided for Pharmaco-therapies • Phase 0 – IV (Phase A – D) • Goal: Bring Therapies with Disease-specific Indications to Market

  7. Interventional Oncology • Ideally Supported by Funded Research • Discovery / development – (Preclinical & ~ Phase 0) • Optimization – (Preclinical and Phase 0 – early II) • Validation for specific cancers / stages – (Phase II – IV) • Regulatory approval – (Later Phase II and III) • Supportive payor policies– (Later Phase II – IV) • Widespread physician acceptance – (Later Phase II – IV) • Patient recognition and “informed” demand

  8. Clinical Trials Nomenclature:Phase 0 – IV vs. Pilot / Pivotal • Pharma Phase 0 – IV • Works for many but not all drug trials • Poor fit for IGI / IO trials based on standard definitions & procedures • FDA/CDRH Pilot and Pivotal Designation • Regulatory purpose • No accepted linkage to “Phase 0 – IV” • Not sufficiently granular for scientific endpoints • Approval process different than CDER/CBER

  9. Clinical Trials Construct:A Proposed Matrix for IO Trials • Phase A – D • A (0 / I, Pilot) – Single site:safety, QA, effect, optimize I & I – lesion, organ, patient • B (I / II, Pilot) – Single / Multi-site:effect,standardize, translate, early data – lesion, organ, early patient level data • C (II, Pilot / Pivotal) – Multi-site:organ/lesion outcome &/or more robust patient level data • D (III / IV, Pivotal) – Multi-site:patient level data, comparative, randomized preferred

  10. IO Clinical Trial Endpoints:Definitions of Success and Failure • IO Therapies often repeatable • Consider adoption of vascular definitions: • Primary Success – result post intent to treat • Primary Assisted Success – add’l Rx, different site • Secondary Success – re-treatment of residual / recurrent disease at previously treated site • Failure – residual, recurrent, new disease • Patient Refuses or Is Ineligible for Added Therapy; Death; etc. • Worthy of Consideration: • Local control • Systemic control • Intent to treat and treatment plan • Purpose of treatment:cure, long-term control, control as bridge therapy, palliation

  11. Interventional OncologyImaging Issues – RECIST, etc. • RECIST Criteria unless modified do not apply • Non-IGI RECIST issues already limiting • Immediate post-IGI lesion larger • Imaging lesion ≠ disease (viable tumor) • Recurrence / residual may not alter lesion dimensions • Validation of imaging findings • Imaging/sensing equivalent of the surgical tumor-free margin – Future interventional oncology; likely multi-parametric, co-registered data: anatomic, physiologic.

  12. NCI IO Initiatives:IO Clinical Trials Infrastructure • Targeted Towards Providing an Infrastructure for Image-Guided, Device-Based Therapy Similar to the Infrastructure Provided for Pharmacotherapies • Phase 0 – IV (Phase A – D) • Goal: Bring Therapies with Disease-specific Indications to Market • Phase II and III Currently Implemented Through Existing Cooperative Groups • Infrastructure is not All or Nothing • Variations in Collaborative Mechanisms • Use of NCIA to Support non-NCI Trial under Specific Conditions

  13. NCI IO Clinical Initiatives: Current • Device Rx Strategy Meetings (2-3 / Year) • Exploratory “By Invitation” Meetings (Stage I and II Breast Cancer) • “Open / Private” Device Rx Development Meetings (Renal Cell Cancer) • Disease / Technology Focused • Multi-purpose (Multilateral Education, Prioritization, Potential Solicitations) • Support for Later Phase Clinical Trials • Collaboration among NCI, FDA, CMS • Strong Ties with Industry (CTA, CSA, pre-IDE, etc.) • Utilizes Cooperative Group Mechanism • Two Protocols in Process NOW

  14. NCI IO Clinical Initiatives: Current • 7th Annual Forum on Biomedical Imaging in Oncology - Feb 1-2, 2007 • Collaboration with NEMA, AdvaMed, MDMA • Will Focus on Opportunities for Collaboration including Clinical Trials • QC and Uncertainty Measurements • SPORE and CC Initiatives • Tissue Acquisition in Early Phase Clinical Trials • Standardized Imaging Protocols During IO Trials • Trans-SPORE Activities

  15. Phase II / III Infrastructure:Current “Implementation” • PI / Industry Collaborator Work Through Cooperative Group to Submit Concept • Considerations - ±IDE, ±CPT, etc. • CSA / CTA between NCI and Industry • Concept Approved • Pre-IDE Meeting with ODE/CDRH/FDA (include NCI, PI, etc.) • Contract between Cooperative Group and Industry • Protocol Developed • IDE Application by NCI (if necessary) • CMS Discussions Regarding Funding Clinical Care • Protocol (and IDE) Approved by NCI and FDA • Protocol Activated (Potential CTSU Listing) • Image Support through NCIA

  16. Conclusion: • IGI methods offer new challenges and possibilities in cancer care • Opportunities for academia, industry, and federal agencies to work closely together to address issues and bring new therapies to the bedside

More Related